-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, DWcznmF3fPjX9QEm7tOSlOwWMCbXbsfkfA49nZfG76nFPYzIUBhDyJDWBBvw7Gyq 07LqoDX0end4EU/hs/7wbQ== 0001179110-05-005539.txt : 20050314 0001179110-05-005539.hdr.sgml : 20050314 20050314204308 ACCESSION NUMBER: 0001179110-05-005539 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20050310 FILED AS OF DATE: 20050314 DATE AS OF CHANGE: 20050314 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LIPID SCIENCES INC/ CENTRAL INDEX KEY: 0000071478 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 430433090 STATE OF INCORPORATION: AZ FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7068 KOLL CENTER PARKWAY STREET 2: SUITE 401 CITY: PLEASANTON STATE: CA ZIP: 94566 BUSINESS PHONE: 925-249-4000 MAIL ADDRESS: STREET 1: 7068 KOLL CENTER PARKWAY STREET 2: SUITE 401 CITY: PLEASANTON STATE: CA ZIP: 94566 FORMER COMPANY: FORMER CONFORMED NAME: NZ CORP DATE OF NAME CHANGE: 20000810 FORMER COMPANY: FORMER CONFORMED NAME: NEW MEXICO & ARIZONA LAND CO DATE OF NAME CHANGE: 19920703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BELLOTTI MARC CENTRAL INDEX KEY: 0001162531 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-00497 FILM NUMBER: 05679873 BUSINESS ADDRESS: STREET 1: 7068 KOLL CENTER PARKWAY STREET 2: SUITE 401 CITY: PLEASANTON STATE: CA ZIP: 94566 BUSINESS PHONE: 9252494000 4 1 edgar.xml FORM 4 - X0202 4 2005-03-10 0 0000071478 LIPID SCIENCES INC/ LIPD 0001162531 BELLOTTI MARC 7068 KOLL CENTER PARKWAY, SUITE 401 PLEASANTON CA 94566-3111 0 1 0 0 VP, Research & Development Stock Option (right to buy) 3.7 2005-03-10 4 A 0 39488 3.7 A 2015-03-09 Common Stock 39488 355390 D The options shall fully vest and be exercisable upon approval by the Federal Drug Administration ("FDA") of the Company's investigatory drug application relating to selective HDL delipidation, provided that such FDA approval occurs on or before March 10, 2006. If FDA approval of such application has not been granted by March 10, 2006, the options will terminate on such date. By Sandra Gardiner, as Attorney-in-Fact on behalf of Marc Bellotti, Vice President of Research & Development 2005-03-14 EX-24 2 exh24mbpow.txt Power of Attorney This will confirm that I have granted each of the individuals listed below the authority to, on my behalf, execute and file the Statement of Changes in Beneficial Ownership of Securities (Form 4) and the Annual Statement of Beneficial Ownership of Securities (Form 5), both filed pursuant to Section 16 of the Securities Exchange Act of 1934, as amended, as my Attorney In Fact. Such power of attorney shall remain in full force and effect until either (i) I am no longer subject to the reporting requirements under Section 16 of the Securities Act of 1933, as amended or (ii) I have provided you with written notice withdrawing this authority. The individuals who are authorized to act as my Attorney-In-Fact under this Power of Attorney are as follows: Deborah S. Lorenz Sandra Gardiner This Power of Attorney is effective immediately upon filing with the Securities Exchange Commission and, for purpose of my future Section 16 reports, replaces and revokes any and all other Powers of Attorney previously filed by me. Very truly yours, _____________________ Marc Bellotti Date: March 14, 2005 -----END PRIVACY-ENHANCED MESSAGE-----